Thursday 16 October, 2025
Introduction: The minimum effective concentration (MEC) of dolutegravir (DTG) is not well defined. Putative trough concentration (Ctrough) targets have been…
Read morePoster: Drug/Disease Modelling - Infection
Ethambutol population pharmacokinetics in South African patients with drug-susceptible tuberculosis
Thursday 16 October, 2025
Objectives: Ethambutol is one of four drugs given during the initial two-month intensive phase of drug-susceptible tuberculosis treatment. Ethambutol is…
Read moreAnalysis of Mycobacterium tuberculosis time to positivity in response to treatment in South African patients with drug-susceptible tuberculosis
Thursday 16 October, 2025
Objectives: Tuberculosis is the leading cause of death from an infectious agent worldwide[1]. Tuberculosis burden is high in South Africa,…
Read morePharmacokinetic-pharmacodynamic modelling to characterize the time-course of meropenem effect in vivo on bacteria with high MIC
Thursday 16 October, 2025
Objectives: Carbapenem resistance represents a serious clinical concern, with multiple carbapenem-resistant species listed as a critical priority for research by…
Read moreTranslation of the in vitro antimicrobial activity of afabicin against Staphylococcus aureus to in vivo bacterial killing dynamics using a pharmacokinetic-pharmacodynamic model based on time-kill experiments
Thursday 16 October, 2025
Introduction: Afabicin is a prodrug of afabicin desphosphono, a first-in-class antibiotic. Afabicin desphosphono is an enoyl-acyl carrier protein reductase (FabI)…
Read morePharmacokinetics of cycloserine in an Indian population with multidrug-resistant tuberculosis.
Thursday 16 October, 2025
Introduction: Cycloserine (CYC) inhibits alanine racemase and D-alanine ligase, two essential enzymes for the cell wall synthesis in Mycobacterium tuberculosis…
Read moreA semi-mechanistic model to characterize the long-term dynamic of HBV markers during treatment with lamivudine and PEG-IFNa
Thursday 16 October, 2025
Objectives: Current treatments for chronic HBV (CHB) infection rely on nucleosid analogs (NUCs) and pegylated interferon (peg-IFNα). These treatments suppress…
Read moreA mechanistic model to characterize the long-term dynamic of HBV markers in Lamivudine and PEG-IFNa treated patients
Thursday 16 October, 2025
Objectives: Chronic hepatitis B remains a major public health threat due to its high infectiousness and its progression to cirrhosis,…
Read moreLefamulin exposure in soft tissues: population pharmacokinetics and pharmacokinetic/pharmacodynamic target attainment
Thursday 16 October, 2025
Objectives: Lefamulin is the first pleuromutilin antibiotic for systemic application in humans, and currently only approved for bacterial community-acquired pneumonia…
Read moreModel-based comparison of antibiotic activity at target-site concentrations: a case study with ceftaroline and lefamulin for soft-tissue infections
Thursday 16 October, 2025
Objectives: Comparing antibiotic activity of different drugs using traditional pharmacokinetic-pharmacodynamic (PK-PD) targets has limitations: the targets may have been derived…
Read more